Molecular genetic sets FarmakoGEN-ACS and FarmakoGEN-SLS6A4 ‘production of GEN received CE-mark

At the end of May 2011 molecular genetic sets "FarmakoGEN-ACS" and "FarmakoGEN-SLS6A4 ‘production of" gene "Group Alcor Bio received CE-mark.

"FarmakoGEN-ACG" — A diagnostic kit for determining individual susceptibility to anticoagulants.
"FarmakoGEN-SLC6A4» — A unique diagnostic kit for the detection of genetic predisposition to mental disorders and determine individual susceptibility to serotonergic antidepressants.

Previously developed by the biotechnology company "gene" test system "Osteogenic M" (A unique diagnostic kit for the detection of genetic predisposition to osteoporosis)


and "TromboGEN" (A diagnostic kit for the detection of hereditary thrombophilia)


received CE-mark in 2010.

The conformity assessment procedure made by the company "gene" product quality standard conducted by MediMark Europe.

CE marking — a sign indicating that the product meets the requirements of the European Union on security products. The practice of the CE marking of products was introduced in Western Europe in the mid-80s in order to increase the efficiency of the processes of trade between the EU and reduce the cost of compliance verification requirements for product safety for the consumer as set out in the Directives of the European Community. The CE mark is often referred to as a "passport products", which allows the manufacturer of any country in the world to sell their products on the European markets.

The company "gene" was created in 2005. The first steps a company committed with the support of the Foundation for Assistance to Small Innovative Enterprises in Science and Technology in the framework of the implementation of the project "Development and commercialization of diagnostic kits for medical and genetic analysis of hereditary diseases and genetic predisposition to multifactorial disease." In this study was obtained by prototype diagnostic test kit genetic predisposition to bone diseases.

In 2007, the development of an interest group of companies "Alcor Bio", which is today one of the most technologically advanced companies in the North-West region of Russia for the production of diagnostic products based on enzyme-linked immunosorbent assay. In the same year there was a merger of companies in which the company "gene" had the opportunity to actively develop new areas of research.

The company is currently conducting research in the field of socially significant diseases such as osteoporosis, cardiovascular disease, cancer, mental disorders, developing a test system for the diagnosis of serious hereditary diseases, including cystic fibrosis using a DNA chip.

The project of "gene" — "Development of a set of" MV25-chip "using nanobiotechnology of DNA microarrays for the diagnosis of cystic fibrosis and violations of human reproductive function" in 2010 won the competition for the award of the Government of St. Petersburg for the best innovative project implemented in the framework of cluster in the category "Best Innovation Project, implemented within the framework of the cluster in the field of medicine, biotechnology and pharmaceuticals."

Like this post? Please share to your friends: